Drug Trial Radar · NCT04442022
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
501
Planned (sponsor's estimate)
Start
Sep 3, 2020
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.
Conditions
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy)Drug
Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Selinexor (combination therapy)Drug
Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Selinexor (combination therapy)Drug
Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Placebo matching for Selinexor (combination therapy)Drug
Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Rituximab (combination therapy)Drug
Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
Rituximab (combination therapy)Drug
Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
Gemcitabine (combination therapy)Drug
Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
Dexamethasone (combination therapy)Drug
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Cisplatin (combination therapy)Drug
Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
Selinexor (continuous therapy)Drug
Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
Placebo matching for Selinexor (continuous therapy)Drug
Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014Time frame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
- Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014Time frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
Locations
38 sites in 6 countries. Site status is shown where the registry gives one.
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Chandler, Arizona
Arizona Oncology Associates
Tucson, Arizona
The Oncology Institute (TOI) Clinical Research
Cerritos, California
Norton Cancer Institute, St. Matthews
Louisville, Kentucky
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Stony Brook
Stony Brook, New York
Texas Oncology - Tyler
Tyler, Texas
The University of Texas Health Science Center at Tyler DBA UT Health East Texas HOPE Cancer Center
Tyler, Texas
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
Huangpu, Shanghai Municipality, China
Zhongshan Hospital Fudan University
Xuhui, Shanghai Municipality, China
Huaxi Hospital Sichuan University
Chengdu, Sichuan, China
The first affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, China
Assuta Ashdod Medical Center
Ashdod, Israel
Soroka Medical Center
Beersheba, Israel
Rabin Medical Center
Petah Tikva, Israel
Assuta Medical Center - Ramat Hachayal
Tel Aviv, Israel
AOU Ospedali Riuniti-Università Politecnica delle Marche Clinica di Ematologia
Ancona, Ancona, Italy
UOC Ematologia ad Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano"
Caserta, Caserta, Italy
National Cancer Institute
Naples, Napoli, Italy
AOU Maggiore della Carità SCDU Ematologia
Novara, Novara, Italy
DIP. Oncologia- Ematologia, UOSD Centro Diagnosie TerapiaDei Linfomi
Pescara, Pescara, Italy
Fondatione Policlinico Universitario A. Gemelli
Rome, Rome, Italy
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Palermo, Sicily, Italy
AOU City of Health and Science of Turin
Turin, Torino, Italy
Institute of Hematology and Transfusion Medicine
Warsaw, Poland
Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
Pratia MCM Krakow
Krakow, Lesser, Poland
Szpitale pomorskie gdynia dept of haematology
Gdynia, Pomeranian Voivodeship, Poland
Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wrocławiu
Wroclaw, Radeckiego, Poland
Pratia Onkologia Katowice
Katowice, Silesian Voivodeship, Poland
CM Pratia Poznań
Skorzewo, Wielkopolska, Poland
Institut català d'oncologia-hospital germans trias i pujol
Badalona, Barcelona, Spain
Hospital Vall Hebron
Barcelona, Barcelona, Spain
Institut Catala D'oncolocia
Barcelona, Barcelona, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital Virgen del Rocío
Seville, Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.